Glaukos ’ iStent Has Strong Showing in 5-Year Data

This study shows that not only are Glaukos’ iStents as effective as once-daily topical travoprost in controlling IOP, but they also succeed at maintaining IOP reductions over the long-term with fewer additional medications.” The San Clemente, CA-based company has been on full court press for a while now. Earlier this year, at the 37th annual J.P. Morgan Healthcare Conference, the company unveiled a series of products and initiatives that would see it transition into a hybrid surgical, pharmaceutical, and medical device company.    
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news